Physician profile
Andre Celestin
NPI 1649230202
$383.56
in general payments reported to CMS, 2019-2025
13 companies · $76.43 in 2025
The $76.43 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.46 · 2020: $65.31 · 2021: $87.03 · 2022: $24.73 · 2023: $73.54 · 2024: $42.06 · 2025: $76.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $154 · Education: $37.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $154.33 |
| Education | $37.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $111.87 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $40.97 | 2023-2024 | Airsupra |
| Novo Nordisk INC | $38.73 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.70 | 2025 | Jardiance |
| Almatica Pharma LLC | $30.08 | 2023 | Loreev Xr, Gralise |
| Amneal Pharmaceuticals LLC | $27.64 | 2023 | Lyvispah |
| Pfizer INC. | $24.96 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.73 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.91 | 2024 | Voquezna |
| Esperion Therapeutics, INC. | $15.51 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.46 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Celestin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.